Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test

NCT ID: NCT00236171

Last Updated: 2010-06-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy of the topical therapies Protopic and Advantan as well as their combination against placebo in a Psoriasis Plaque Test

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

daily psoriasis plaque tests for two weeks and optical coherence tomography (OCT) and 20-MHz-ultrasound on day 0 and day 11, 10 days post end of treatment and 20 days post end of treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Protopic, Advantan

Intervention Type DRUG

Blood and Urine Test

Intervention Type PROCEDURE

coherence tomography

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients older than 18 Years
* Negative urine pregnancy test
* Written informed consent
* Good compliance

Exclusion Criteria

* Patients less than 18 years
* Pregnant patients
* Patients with renal insufficiency, liver diseases
* Patients who received systemic antipsoriatic treatment or UV treatment less than 4 weeks prior to study
* Patients who used topical antipsoriatics within two weeks prior to study
* Immunosuppressed Patients
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Technische Universität Dresden

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Technical University Dresden

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gottfried Wozel, Professor

Role: PRINCIPAL_INVESTIGATOR

Technische Universität Dresden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Technische Universität Dresden

Dresden, Saxony, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ETAPSO

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.